Acipimox in the treatment of patients with hyperlipidaemia: A double blind trial

  • Ball M
  • Vella M
  • Rechlass J
 et al. 
  • 1


    Mendeley users who have this article in their library.
  • 19


    Citations of this article.


Fifty-two patients with Fredrickson Type IIb or Type IV hyperlipidaemia, in whom diet had not achieved satisfactory lipid levels, completed a double blind randomised study of acipimox versus placebo. The patients were given acipimox, 250 mg three times daily or placebo for a three month period, and plasma lipids and glucose were monitored. The patients receiving acipimox showed a fall in the mean concentration of plasma triglyceride compared to placebo (0.74 mmol/l) and this was most marked in patients whose initial plasma triglyceride levels were greater than 3 mmol/l (1.0 mmol/l, confidence limits 0.18, 1.82). Acipimox was well tolerated, and could be a useful addition to the drugs available for the treatment of patients with hypertriglyceridaemia.

Author-supplied keywords

  • acipimox
  • adverse effects
  • hyperlipidaemia
  • plasma glucose

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • M. J. Ball

  • M. Vella

  • J. P.D. Rechlass

  • D. B. Jones

  • C. Stirling

  • J. I. Mann

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free